Cargando…

Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus

BACKGROUND: Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive. METHODS: We searched PubMed and Embase for data extracted from inception to July 14, 2020, with a r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tian, Providencia, Rui, Mu, Nan, Yin, Yue, Chen, Mai, Wang, Yishi, Liu, Manling, Yu, Lu, Gu, Chunhu, Ma, Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847575/ https://www.ncbi.nlm.nih.gov/pubmed/33516224 http://dx.doi.org/10.1186/s12933-020-01202-5

Ejemplares similares

Metformin mediates cardioprotection against aging‐induced ischemic necroptosis
por: Li, Chen, et al.
Publicado: (2020)

Metformin-Enhanced Cardiac AMP-Activated Protein Kinase/Atrogin-1 Pathways Inhibit Charged Multivesicular Body Protein 2B Accumulation in Ischemia–Reperfusion Injury
por: Li, Tian, et al.
Publicado: (2021)

Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
por: Fung, Colman Siu Cheung, et al.
Publicado: (2015)

SIRT6 in Senescence and Aging-Related Cardiovascular Diseases
por: Li, Xiaokang, et al.
Publicado: (2021)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation
por: Ram, Eilon, et al.
Publicado: (2019)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Aerobic Interval Training Regulated SIRT3 Attenuates High-Fat-Diet-Associated Cognitive Dysfunction
por: Shi, Zhaoling, et al.
Publicado: (2018)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus
por: Younas, Amna, et al.
Publicado: (2021)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
por: Ma, J., et al.
Publicado: (2014)

Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand
por: Horsburgh, Simon, et al.
Publicado: (2021)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
por: Rombopoulos, Grigorios, et al.
Publicado: (2015)

Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
por: Lunder, Mojca, et al.
Publicado: (2018)

Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
por: Gao, Chao, et al.
Publicado: (2020)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients
por: Firouzjaei, A, et al.
Publicado: (2016)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
por: Zhu, Hongmei, et al.
Publicado: (2013)

Monotherapy in patients with type 2 diabetes mellitus
por: Rhee, Sang Youl, et al.
Publicado: (2017)

Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Rhee, Sang Youl, et al.
Publicado: (2017)

Retinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease
por: Heitmar, R., et al.
Publicado: (2017)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Yoo, Soon-Jib, et al.
Publicado: (2021)

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
por: Caturano, Alfredo, et al.
Publicado: (2023)

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
por: Thein, David, et al.
Publicado: (2020)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Comparison of Mitochondrial Adenosine Triphosphate–Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin
por: Wang, Meng-Ting, et al.
Publicado: (2022)

Rapid Integration of Multi-copy Transgenes Using Optogenetic Mutagenesis in Caenorhabditis elegans
por: Noma, Kentaro, et al.
Publicado: (2018)

Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial
por: Gillani, Syed Wasif, et al.
Publicado: (2017)

Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis
por: Mykoniatis, Ioannis, et al.
Publicado: (2021)

Early cardiovascular events in women with a history of gestational diabetes mellitus
por: Goueslard, Karine, et al.
Publicado: (2016)

Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus
por: Lekva, Tove, et al.
Publicado: (2017)

Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study
por: Bromage, Daniel I., et al.
Publicado: (2019)

Altered Function of the DnaJ Family Cochaperone DNJ-17 Modulates Locomotor Circuit Activity in a Caenorhabditis elegans Seizure Model
por: Takayanagi-Kiya, Seika, et al.
Publicado: (2016)

Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels
por: Parker, William A. E., et al.
Publicado: (2020)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ed5pqaga117epdbfc06kh5plon